We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Tests Evaluated for Lymphatic Filariasis Diagnosis

By LabMedica International staff writers
Posted on 03 Jan 2016
Print article
The BinaxNOW immunochromatographic tests for Wuchereria bancrofti
The BinaxNOW immunochromatographic tests for Wuchereria bancrofti (Photo courtesy of Abbott Rapid Diagnostics)
Diagnostic tools for lymphatic filariasis (LF) elimination programs are useful in mapping the distribution of the disease, delineating areas where mass drug administrations (MDA) are required, and determining when to stop MDA.

The prevalence and burden of LF have been drastically reduced following mass treatments, and the evaluation of the performance of circulating filarial antigen (CFA)-based assays was acknowledged to be of high interest in areas with low residual LF endemicity rates after multiple rounds of MDA.

Scientists at the University of Yaoundé (Cameroon) studied an area delimited by four health districts known as an historical focus of LF, with prevalence ranging from 0.4% to 22.1%, but where no mass antifilarial intervention was ever performed before the outset of the survey. All volunteers underwent clinical examination for LF clinical signs, and blood sample collection for prevalence and intensity of the infection.

Calibrated thick blood smears (CTBS), immunochromatographic test (ICT) and Og4C3 enzyme-linked immunosorbent assay (ELISA) were carried out by night to identify Wuchereria bancrofti microfilarial and circulating filarial antigen carriers. A threshold determination assay regarding ICT and ELISA was performed using serial plasma dilutions from individuals with positive microfilarial counts. The ICT is a rapid card test manufactured by BinaxNow (Scarborough, ME, USA) for the detection of 200 kDa W. bancrofti circulating filarial antigen (CFA). The Og4C3 ELISA test kit is specific for W. Bancrofti CFA, and is manufactured by TropBio Pty Ltd. (Sydney, NSW, Australia).

All 404 individuals were tested for ICT, ELISA and CTBS. CFA was detected in 11 (2.7%;) enrollees using ICT and in 28 (6.9%) individuals using ELISA, the difference being significant. CTBS revealed that seven (1.7%) of these 404 individuals harbored microfilariae (mf), with an intensity of infection of 7.49 mf/mL. All individuals harboring microfilariae as indicated on a positive blood films were detected by ICT and ELISA, but among individuals positive for ELISA, only 35.7% of them were detected using ICT indicating a moderate agreement between both tests. Threshold determination analyses showed that ICT was positive at some dilution factors for different plasma samples, but ELISA was still positive at the last plasma dilution for which ICT yielded a negative result.

The authors concludes that their findings suggest a loss of sensitivity for ICT in low endemicity settings, especially in people exhibiting low levels of circulating filarial antigen, raising serious concern regarding the monitoring and evaluation procedures in the framework of LF elimination program. The study was published on December 23, 2015, in journal BMC Infectious Diseases.

Related Links:

University of Yaoundé 
BinaxNow 
TropBio Pty Ltd. 


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
HbA1c Test
HbA1c Rapid Test
New
Epstein-Barr Virus Test
Mononucleosis Rapid Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.